IMUX•benzinga•
Immunic Says Oral IMU-856 Demonstrated Dose-Dependent Increase Of GLP-1 In Celiac Disease Patients And Corresponding Effects in Preclinical Testing
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga